Welcome to Roche Foundation Medicine.

This site is not intended to provide medical advice and/or treatment guidance. It is produced by Roche as a partner of Foundation Medicine.

Please select an option:

!
We use cookies to help provide you with a better service. You can change your cookie settings at any time. Otherwise, we will assume you're OK to continue.
×
Menu
Close
Our Genomic Testing PortfolioFoundationOne CDxFoundationOne LiquidFoundationOne Heme

 

 

Our portfolio  

High-quality portfolio

A portfolio of extensively validated comprehensive profiling services to guide treatment and research decisions at optimal times beneficial to your patients’ journeys

Foundation Medicine’s portfolio of extensively validated comprehensive genomic profiling services provides powerful insights to guide efficient, personalised treatment decisions at optimal times beneficial to your patients’ journeys:1–8

Solid tumourTissue sampleBlood sample

Explore FoundationOne CDx Explore FoundationOne CDx
Explore FoundationOne Liquid CDx Explore FoundationOne Liquid CDx
Explore FoundationOne Heme Explore FoundationOne Heme
All our services use our leading comprehensive genomic profiling approach to identify clinically relevant alterations and potentially expand treatment options

 

 

 

 

All of Foundation Medicine’s services use our leading comprehensive genomic profiling approach, which broadly analyses the tumour genome to identify clinically relevant alterations and potentially expands patients’ treatment options.1,2,4,5,7–13
Learn more about comprehensive genomic profilling

Genomic database

As our understanding of cancer evolves, so do our tests

Our continuously growing genomic database currently includes over 400,000 genomic profiles in over 150 common and rare tumour subtypes. Advanced bioinformatics interpret the data, including rare and complex alterations, to generate powerful insights.14 Our tests are constantly evolving to capture the most clinically relevant genomic alterations so you stay up-to-date and the latest treatment options can be considered.1,2,4,5

Our growing database includes 200,000+ genomic profiles, allowing our tests to constantly evolve so we can provide the most clinically relevant insights
References
  1. Frampton GM et al. Nat Biotechnol 2013; 31: 1023–1031.
  2. FoundationOne®CDx Technical Specifications, 2018. Available at: www.rochefoundationmedicine.com/f1cdxtech (Accessed August 2020).
  3. FoundationOne®CDx FDA Approval, 2017. Available at: 
    https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170019a.pdf (Accessed August 2020).
  4. Data on file: FoundationOne Liquid CDx Technical Specifications, 2020. Available at: http://www.eifu.online/FMI/190070862 (Accessed August 2020).
  5. Data on file: Clinical and analytical validation data file for FoundationOne Liquid CDx.
  6. FoundationOne Liquid CDx FDA Approval, 2020. Available at: www.foundationmedicine.com/press-releases/445c1f9e-6cbb-488b-84ad-5f133612b721 (Accessed August 2020).
  7. FoundationOne®Heme Technical Specifications, 2017. Available at: www.foundationmedicine.com/genomic-testing/foundation-one-heme (Accessed August 2020).
  8. He J et al. Blood 2016; 127: 3004–3014.
  9. Drilon A et al. Clin Cancer Res 2015; 21: 3631–3639.
  10. Rankin A et al. Oncologist 2016; 21: 1306–1314.
  11. Ross JS et al. Cancer 2016; 122: 2654–2662.
  12. Suh JH et al. Oncologist 2016; 21: 684–691.
  13. Hirshfield KM et al. Oncologist 2016; 21: 1315–1325.
  14. Foundation Insights. Available at: https://www.foundationmedicine.com/insights-and-trials/foundation-insights (Accessed August 2020).